| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy.
|
J Urol
|
2010
|
6.01
|
|
2
|
Impact of 5α-reductase inhibitors on men followed by active surveillance for prostate cancer.
|
Eur Urol
|
2010
|
3.41
|
|
3
|
Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer.
|
AJR Am J Roentgenol
|
2007
|
3.12
|
|
4
|
Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities.
|
J Urol
|
2007
|
2.69
|
|
5
|
Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy.
|
J Urol
|
2013
|
2.53
|
|
6
|
The uncertainty of radio frequency treatment of renal cell carcinoma: findings at immediate and delayed nephrectomy.
|
J Urol
|
2002
|
2.48
|
|
7
|
Evidence for a biopsy derived grade artifact among larger prostate glands.
|
J Urol
|
2006
|
2.23
|
|
8
|
Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators.
|
J Clin Oncol
|
2011
|
2.21
|
|
9
|
Assessing individual risk for prostate cancer.
|
J Clin Oncol
|
2007
|
2.13
|
|
10
|
Association between germline HOXB13 G84E mutation and risk of prostate cancer.
|
J Natl Cancer Inst
|
2012
|
2.06
|
|
11
|
Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI.
|
J Magn Reson Imaging
|
2009
|
1.88
|
|
12
|
A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis.
|
J Urol
|
2006
|
1.71
|
|
13
|
Do older men benefit from curative therapy of localized prostate cancer?
|
J Clin Oncol
|
2003
|
1.70
|
|
14
|
Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy.
|
Int J Radiat Oncol Biol Phys
|
2007
|
1.66
|
|
15
|
Population based survival data on urachal tumors.
|
J Urol
|
2006
|
1.55
|
|
16
|
Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance.
|
J Urol
|
2013
|
1.54
|
|
17
|
Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome.
|
J Urol
|
2006
|
1.53
|
|
18
|
'Prostatic evasive anterior tumours': the role of magnetic resonance imaging.
|
BJU Int
|
2009
|
1.48
|
|
19
|
Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort study.
|
J Urol
|
2012
|
1.47
|
|
20
|
Physical activity and quality of life after radical prostatectomy.
|
Can Urol Assoc J
|
2010
|
1.44
|
|
21
|
Radical prostatectomy in obese patients: Improved surgical outcomes in recent years.
|
Int J Urol
|
2010
|
1.41
|
|
22
|
Utility of incorporating genetic variants for the early detection of prostate cancer.
|
Clin Cancer Res
|
2009
|
1.39
|
|
23
|
Personal digital assistant data capture: the future of quality of life measurement in prostate cancer treatment.
|
J Oncol Pract
|
2007
|
1.39
|
|
24
|
Treatment planning and dose analysis for interstitial photodynamic therapy of prostate cancer.
|
Phys Med Biol
|
2009
|
1.39
|
|
25
|
Prostate tissue composition and MR measurements: investigating the relationships between ADC, T2, K(trans), v(e), and corresponding histologic features.
|
Radiology
|
2010
|
1.36
|
|
26
|
Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy.
|
Cancer
|
2007
|
1.35
|
|
27
|
Techniques for delivery and monitoring of TOOKAD (WST09)-mediated photodynamic therapy of the prostate: clinical experience and practicalities.
|
J Photochem Photobiol B
|
2005
|
1.34
|
|
28
|
Impact of positive surgical margins after radical prostatectomy differs by disease risk group.
|
J Urol
|
2010
|
1.33
|
|
29
|
Prostate gland: MR imaging appearance after vascular targeted photodynamic therapy with palladium-bacteriopheophorbide.
|
Radiology
|
2007
|
1.29
|
|
30
|
Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2--sparse versus dense cancers.
|
Radiology
|
2008
|
1.28
|
|
31
|
Focal laser ablation for prostate cancer followed by radical prostatectomy: validation of focal therapy and imaging accuracy.
|
Eur Urol
|
2010
|
1.25
|
|
32
|
Association of tissue promoter methylation levels of APC, TGFβ2, HOXD3 and RASSF1A with prostate cancer progression.
|
Int J Cancer
|
2011
|
1.25
|
|
33
|
Patient and community preferences for outcomes in prostate cancer: implications for clinical policy.
|
Med Care
|
2003
|
1.23
|
|
34
|
Delay in surgical therapy for clinically localized prostate cancer and biochemical recurrence after radical prostatectomy.
|
Can J Urol
|
2003
|
1.17
|
|
35
|
Single nucleotide polymorphism of the human kallikrein-2 gene highly correlates with serum human kallikrein-2 levels and in combination enhances prostate cancer detection.
|
J Clin Oncol
|
2003
|
1.16
|
|
36
|
Sexual dysfunction after radical prostatectomy: prevalence, treatments, restricted use of treatments and distress.
|
J Urol
|
2005
|
1.14
|
|
37
|
Transperitoneal laparoscopic prostatectomy does not increase small bowel within the target volume for postoperative radiotherapy.
|
J Urol
|
2009
|
1.13
|
|
38
|
Evidence of multifocality of telomere erosion in high-grade prostatic intraepithelial neoplasia (HPIN) and concurrent carcinoma.
|
Oncogene
|
2003
|
1.11
|
|
39
|
Canadian guidelines for the management of benign prostatic hyperplasia.
|
Can J Urol
|
2005
|
1.10
|
|
40
|
Reliability and validity of the PORPUS, a combined psychometric and utility-based quality-of-life instrument for prostate cancer.
|
J Clin Epidemiol
|
2005
|
1.09
|
|
41
|
Photodynamic therapy for urological malignancies: past to current approaches.
|
J Urol
|
2006
|
1.07
|
|
42
|
Androgen induces adaptation to oxidative stress in prostate cancer: implications for treatment with radiation therapy.
|
Neoplasia
|
2007
|
1.05
|
|
43
|
The use of genetic markers to determine risk for prostate cancer at prostate biopsy.
|
Clin Cancer Res
|
2005
|
1.02
|
|
44
|
DNA methylation of HOXD3 as a marker of prostate cancer progression.
|
Lab Invest
|
2010
|
1.01
|
|
45
|
Changes in health utilities and health-related quality of life over 12 months following radical prostatectomy.
|
Can Urol Assoc J
|
2009
|
1.01
|
|
46
|
Focal therapy in prostate cancer: modalities, findings and future considerations.
|
Nat Rev Urol
|
2010
|
1.00
|
|
47
|
Real-time magnetic resonance imaging-guided focal laser therapy in patients with low-risk prostate cancer.
|
Eur Urol
|
2010
|
0.99
|
|
48
|
Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer.
|
Clin Cancer Res
|
2012
|
0.98
|
|
49
|
New variants at 10q26 and 15q21 are associated with aggressive prostate cancer in a genome-wide association study from a prostate biopsy screening cohort.
|
Cancer Biol Ther
|
2011
|
0.98
|
|
50
|
Variants of the hK2 protein gene (KLK2) are associated with serum hK2 levels and predict the presence of prostate cancer at biopsy.
|
Clin Cancer Res
|
2006
|
0.98
|
|
51
|
Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2003
|
0.98
|
|
52
|
A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer.
|
Am J Clin Oncol
|
2010
|
0.97
|
|
53
|
Radical prostatectomy as treatment for prostate cancer.
|
CMAJ
|
2003
|
0.96
|
|
54
|
Prostate cancer localization with multispectral MRI using cost-sensitive support vector machines and conditional random fields.
|
IEEE Trans Image Process
|
2010
|
0.96
|
|
55
|
Assessment of cutaneous photosensitivity of TOOKAD (WST09) in preclinical animal models and in patients.
|
Photochem Photobiol
|
2005
|
0.94
|
|
56
|
Serial personal digital assistant data capture of health-related quality of life: a randomized controlled trial in a prostate cancer clinic.
|
Health Qual Life Outcomes
|
2007
|
0.94
|
|
57
|
Exploring gay couples' experience with sexual dysfunction after radical prostatectomy: a qualitative study.
|
J Sex Marital Ther
|
2013
|
0.92
|
|
58
|
Male BRCA1 and BRCA2 mutation carriers: a pilot study investigating medical characteristics of patients participating in a prostate cancer prevention clinic.
|
Prostate
|
2005
|
0.92
|
|
59
|
A randomized trial of aerobic versus resistance exercise in prostate cancer survivors.
|
J Aging Phys Act
|
2012
|
0.90
|
|
60
|
The burden of prostate cancer in Canada.
|
Can Urol Assoc J
|
2009
|
0.90
|
|
61
|
The effect of nerve-sparing surgery on patient-reported continence post-radical prostatectomy.
|
Can Urol Assoc J
|
2009
|
0.89
|
|
62
|
In-bore MRI interventions: current status and future applications.
|
Curr Opin Urol
|
2015
|
0.89
|
|
63
|
Do the benefits of finasteride outweigh the risks in the prostate cancer prevention trial?
|
J Urol
|
2006
|
0.89
|
|
64
|
A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer.
|
Cancer Gene Ther
|
2003
|
0.88
|
|
65
|
Focal laser ablation for localized prostate cancer.
|
J Endourol
|
2010
|
0.88
|
|
66
|
MRI for men undergoing active surveillance or with rising PSA and negative biopsies.
|
Nat Rev Urol
|
2010
|
0.88
|
|
67
|
The effect of meeting physical activity guidelines for cancer survivors on quality of life following radical prostatectomy for prostate cancer.
|
J Cancer Surviv
|
2013
|
0.86
|
|
68
|
Cardiovascular effects of androgen depletion and replacement therapy.
|
Urology
|
2006
|
0.85
|
|
69
|
Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk.
|
Cancer Epidemiol Biomarkers Prev
|
2005
|
0.85
|
|
70
|
Contrast-enhanced ultrasonography for real-time monitoring of interstitial laser thermal therapy in the focal treatment of prostate cancer.
|
Can Urol Assoc J
|
2009
|
0.84
|
|
71
|
Evaluation and prognostic significance of ACAT1 as a marker of prostate cancer progression.
|
Prostate
|
2013
|
0.83
|
|
72
|
Focal magnetic resonance guided focused ultrasound for prostate cancer: Initial North American experience.
|
Can Urol Assoc J
|
2012
|
0.82
|
|
73
|
Catastrophic sepsis and hemorrhage following transrectal ultrasound guided prostate biopsies.
|
Can Urol Assoc J
|
2010
|
0.81
|
|
74
|
Nomogram prediction for prostate cancer and aggressive prostate cancer at time of biopsy: utilizing all risk factors and tumor markers for prostate cancer.
|
Can J Urol
|
2006
|
0.81
|
|
75
|
MRI and contrast-enhanced ultrasound monitoring of prostate microwave focal thermal therapy: an in vivo canine study.
|
J Magn Reson Imaging
|
2008
|
0.81
|
|
76
|
Gleason grading controversies: what the chemoprevention trials have taught us.
|
Can Urol Assoc J
|
2009
|
0.81
|
|
77
|
Evolution from active surveillance to focal therapy in the management of prostate cancer.
|
Future Oncol
|
2011
|
0.81
|
|
78
|
Examining risk perception among men with a family history of prostate cancer.
|
Patient Educ Couns
|
2011
|
0.81
|
|
79
|
Prehabilitation for men undergoing radical prostatectomy: a multi-centre, pilot randomized controlled trial.
|
BMC Surg
|
2014
|
0.80
|
|
80
|
Making sense of prostate specific antigen: improving its predictive value in patients undergoing prostate biopsy.
|
J Urol
|
2006
|
0.80
|
|
81
|
Health-related quality of life following radical prostatectomy: long-term outcomes.
|
Qual Life Res
|
2014
|
0.80
|
|
82
|
Does nerve-sparing radical prostatectomy increase the risk of positive surgical margins and biochemical progression?
|
Urol Ann
|
2010
|
0.79
|
|
83
|
Relaxin receptor antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts.
|
Endocr Relat Cancer
|
2014
|
0.79
|
|
84
|
Variation in patterns of practice in diagnosing screen-detected prostate cancer.
|
BJU Int
|
2004
|
0.79
|
|
85
|
Interstitial microwave thermal therapy for prostate cancer.
|
J Endourol
|
2003
|
0.79
|
|
86
|
Construction and evaluation of an anatomically correct multi-image modality compatible phantom for prostate cancer focal ablation.
|
J Urol
|
2010
|
0.79
|
|
87
|
Exercise effects on adipokines and the IGF axis in men with prostate cancer treated with androgen deprivation: A randomized study.
|
Can Urol Assoc J
|
2013
|
0.78
|
|
88
|
The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers.
|
Can Urol Assoc J
|
2011
|
0.78
|
|
89
|
Development of an MRI-compatible device for prostate focal therapy.
|
Med Image Comput Comput Assist Interv
|
2012
|
0.77
|
|
90
|
Oncologic outcomes following radical prostatectomy in the active surveillance era.
|
Can Urol Assoc J
|
2013
|
0.77
|
|
91
|
Perineural invasion on prostate biopsy does not predict adverse pathological outcome.
|
Can J Urol
|
2012
|
0.77
|
|
92
|
Focal therapy for localized prostate cancer -choosing the middle ground.
|
Can Urol Assoc J
|
2009
|
0.76
|
|
93
|
Optimizing contrast agent concentration and spoiled gradient echo pulse sequence parameters for catheter visualization in MR-guided interventional procedures: an analytic solution.
|
Magn Reson Med
|
2013
|
0.76
|
|
94
|
The importance of quality indicators: a call to action.
|
Can Urol Assoc J
|
2009
|
0.76
|
|
95
|
Correlation of the primary Gleason pattern on prostate needle biopsy with clinico-pathological factors in Gleason 7 tumors.
|
Can J Urol
|
2004
|
0.75
|
|
96
|
A system for MRI-guided transperineal delivery of needles to the prostate for focal therapy.
|
Med Phys
|
2013
|
0.75
|
|
97
|
Fifth joint meeting of the American Urological Association and the Japanese Urological Association International Affiliate Society Meeting at the 105th Annual Meeting of the American Urological Association.
|
Int J Urol
|
2010
|
0.75
|
|
98
|
Effect of healthcare provider characteristics on nodal yield at radical cystectomy.
|
Urology
|
2008
|
0.75
|